Cofrogliptin

Cofrogliptin
Clinical data
Other names	HSK7653
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name (2R,3S,5R,6S)-2-(2,5-Difluorophenyl)-5-(2-methylsulfonyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5-yl)-6-(trifluoromethyl)oxan-3-amine;
CAS Number	1844874-26-5 ;
PubChem CID	118613788 ;
ChemSpider	115037226 ;
UNII	LH4G6K6NKP ;
ChEMBL	ChEMBL4646510 ;
Chemical and physical data
Formula	C18H19F5N4O3S
Molar mass	466.43 g·mol−1

Last updated October 27, 2025

Cofrogliptin (developmental name HSK7653) is a long-acting DPP4 inhibitor dosed once every two weeks.^[1]^[2]^[3]^[4]

References

↑ Ji, Linong; Bian, Fang; Pan, Tianrong; Jiang, Hongwei; Jiang, Chengxia; Ren, Qian (20 June 2023). "55-OR: HSK7653, a Novel Ultralong-Acting DPP-4 Inhibitor, as Monotherapy in Patients With Type 2 Diabetes—A Randomized, Double-Blind, Placebo-Controlled Phase III Trial". Diabetes. 72 (Supplement_1) 55-OR. doi:10.2337/db23-55-OR. S2CID 259433641.
↑ Zhang, Miao; Zhang, Shudong; Yu, Zhiheng; Yao, Xueting; Lei, Zihan; Yan, Pangke; Wu, Nan; Wang, Xu; Hu, Qin; Liu, Dongyang (October 2023). "Dose decision of HSK7653 oral immediate release tablets in specific populations clinical trials based on mechanistic physiologically-based pharmacokinetic model". European Journal of Pharmaceutical Sciences. 189 106553. doi: 10.1016/j.ejps.2023.106553 . PMC 10485820 . PMID 37532063.
↑ Liu, Yang; Yan, Shuai; Liu, Jie; Liu, Hongzhong; Song, Ling; Yao, Xueting; Jiang, Ji; Li, Fangqiong; Du, Ke; Liu, Dongyang; Hu, Pei (May 2023). "Development and validation of an HPLC coupled with tandem mass spectrometry method for the determination of HSK7653, a novel super long-acting dipeptidyl peptidase-4 inhibitor, in human plasma and urine and its application to a pharmacokinetic study". Biomedical Chromatography. 37 (5) e5607. doi:10.1002/bmc.5607. PMID 36802077. S2CID 257048524.
↑ Bai, Nan; Wang, Jin; Liang, Wenxin; Gao, Leili; Cui, Wei; Wu, Qinghe; Li, Fangqiong; Ji, Linong; Cai, Yun (6 November 2023). "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, and Dose-Increasing Study on the Safety, Tolerability and PK/PD of Multiple Doses of HSK7653 by Oral Administration in Patients with Type 2 Diabetes Mellitus in China". Diabetes Therapy. 15 (1): 183–199. doi: 10.1007/s13300-023-01496-0 . PMC 10786778 . PMID 37930584.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Ji, Linong; Bian, Fang; Pan, Tianrong; Jiang, Hongwei; Jiang, Chengxia; Ren, Qian (20 June 2023). "55-OR: HSK7653, a Novel Ultralong-Acting DPP-4 Inhibitor, as Monotherapy in Patients With Type 2 Diabetes—A Randomized, Double-Blind, Placebo-Controlled Phase III Trial". Diabetes. 72 (Supplement_1) 55-OR. doi:10.2337/db23-55-OR. S2CID 259433641.

[2] Zhang, Miao; Zhang, Shudong; Yu, Zhiheng; Yao, Xueting; Lei, Zihan; Yan, Pangke; Wu, Nan; Wang, Xu; Hu, Qin; Liu, Dongyang (October 2023). "Dose decision of HSK7653 oral immediate release tablets in specific populations clinical trials based on mechanistic physiologically-based pharmacokinetic model". European Journal of Pharmaceutical Sciences. 189 106553. doi: 10.1016/j.ejps.2023.106553 . PMC 10485820 . PMID 37532063.

[3] Liu, Yang; Yan, Shuai; Liu, Jie; Liu, Hongzhong; Song, Ling; Yao, Xueting; Jiang, Ji; Li, Fangqiong; Du, Ke; Liu, Dongyang; Hu, Pei (May 2023). "Development and validation of an HPLC coupled with tandem mass spectrometry method for the determination of HSK7653, a novel super long-acting dipeptidyl peptidase-4 inhibitor, in human plasma and urine and its application to a pharmacokinetic study". Biomedical Chromatography. 37 (5) e5607. doi:10.1002/bmc.5607. PMID 36802077. S2CID 257048524.

[4] Bai, Nan; Wang, Jin; Liang, Wenxin; Gao, Leili; Cui, Wei; Wu, Qinghe; Li, Fangqiong; Ji, Linong; Cai, Yun (6 November 2023). "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, and Dose-Increasing Study on the Safety, Tolerability and PK/PD of Multiple Doses of HSK7653 by Oral Administration in Patients with Type 2 Diabetes Mellitus in China". Diabetes Therapy. 15 (1): 183–199. doi: 10.1007/s13300-023-01496-0 . PMC 10786778 . PMID 37930584.

[1]

[2]

[3]

[4]